Exceptional Use Recommendation for Nuclear Emergency Drug
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended an exceptional circumstances marketing authorization for Imreplys. The drug — active ingredient sargramostim and manufactured by Partner Therapeutics Ltd — is intended to treat people with hematopoietic acute radiation syndrome (H-ARS) following acute exposure to myelosuppressive doses of radiation.
H-ARS occurs when radiation suppresses bone marrow hematopoiesis, leading to an increased risk for infection and bleeding. It occurs after whole-body radiation doses of about 1-6 Gy, most often associated with acute exposure following radiologic or nuclear emergencies. Sargramostim, a granulocyte-macrophage colony-stimulating factor, counteracts H-ARS by inducing the bone marrow to produce immune-protective leukocytes, including granulocytes, macrophages, and monocytes, as well as red blood cells and platelets.
The positive opinion means that Imreplys is now indicated for treatment of patients of all ages with H-ARS following acute exposure to myelosuppressive doses of radiation. It has also been used in the US in patients aged 2 years or older to prevent serious infection in conditions such as leukemia, bone marrow transplant, and prechemotherapy blood cell collection.
As well as the infection risk, symptoms of H-ARS may include those of anemia, petechiae, and prolonged bleeding, starting 1-6 hours after exposure and lasting up to 2 days.
Exceptional Circumstances Authorization Recommended
Medicines can be authorized under exceptional circumstances, subject to certain specific obligations where the applicant was unable to provide comprehensive data on the efficacy and safety of the medicine under normal conditions of use. This may be because the condition that the drug is to be used for is too rare for extensive data gathering; because of limited scientific knowledge in the area concerned; or because collection of full information is not possible or is unethical. Exceptional circumstances authorization must be reviewed annually.
The CHMP said that three randomized, blinded, placebo-controlled studies in rhesus monkeys who received H-ARS-inducing total body irradiation showed that Imreplys increased 60-day survival rates compared with placebo. Studies had also shown faster recovery of absolute neutrophil counts and platelets, reduced infection rates, and fewer signs of sepsis.
The most common side effects with Imreplys include fever, diarrhea, vomiting, skin reactions, rash, asthenia, metabolic laboratory abnormalities, malaise, high glucose, abdominal pain, weight loss, low albumin, pruritus, gastrointestinal hemorrhage, chills, pharyngitis, bone pain, chest pain, hypomagnesemia, hematemesis, arthralgia, anxiety, and eye hemorrhage.
Use Governed by Radiologic/Nuclear Emergency Recommendations
The EMA said that Imreplys will be available as a 250 μg powder for solution for injection and should be used in accordance with official radiologic/nuclear emergency recommendations.
Detailed recommendations for the use of the product will be described in the summary of product characteristics (SmPC), which will be published on the EMA website in all official European Union languages after the marketing authorization has been granted by the European Commission.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
12 minutes ago
- Wall Street Journal
Health Insurers to Promise Changes to Preapproval Process That Drew Backlash
Following the backlash that hit health insurers after the killing of a top executive last year, the industry will pledge steps meant to smooth the controversial preapproval process that can deny or delay access to care. The initiative is set to be unveiled early next week, according to people familiar with the matter.
Medscape
24 minutes ago
- Medscape
Darzalex Monotherapy OK'd for Smoldering Multiple Myeloma
At its June 2025 meeting, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended extending the indications for Darzalex (daratumumab) solution for injection as monotherapy to the treatment of adult patients with smoldering multiple myeloma at high risk of developing multiple myeloma. Darzalex is a monoclonal antibody used to treat adults with multiple myeloma and light chain amyloidosis. Good Response to Treatment Daratumumab attaches to the CD38 protein, found in large amounts on abnormal white blood cells in multiple myeloma and light chain amyloidosis. By attaching to CD38 on these cells, daratumumab activates the immune system to kill the abnormal white blood cells. Darzalex as monotherapy was investigated in two main studies involving multiple myeloma patients whose disease relapsed after, or was refractory to, at least two previous treatments, including a proteasome inhibitor and an immunomodulatory medicine. Response to treatment was measured by the disappearance of, or at least a 50% reduction in, protein produced by multiple myeloma cells. In the first study, around 29% of the patients who received daratumumab responded to treatment. In the second study, 36% of patients responded. In these studies, daratumumab was not compared with any other treatment. Full Indications The CHMP highlighted that the full indications for Darzalex solution for injection for will now be: For multiple myeloma: In combination with lenalidomide and dexamethasone or with bortezomib, melphalan, and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant In combination with bortezomib, lenalidomide, and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma In combination with bortezomib, thalidomide, and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant In combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy In combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide-refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy As monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy For smoldering multiple myeloma: As monotherapy for the treatment of adult patients with smoldering multiple myeloma at high risk of developing multiple myeloma For light chain (AL) amyloidosis: In combination with cyclophosphamide, bortezomib, and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain amyloidosis The indications for Darzalex concentrate for solution for infusion remained unchanged, the CHMP said. Rob Hicks is a retired UK National Health Service doctor. A well-known TV and radio broadcaster, he has written several books and has regularly contributed to national newspapers, magazines, and online publications.
Medscape
38 minutes ago
- Medscape
Do Tattoos Pose a Cancer Risk?
Over recent decades, tattoos have rapidly gained in popularity, with a Narrative Research survey in 2024 showing that 31% of the adult Canadian population has tattoos. Moreover, women are much more inclined to get a tattoo, including permanent makeup, than men (38% vs 28%). In Canada, the US, and Europe, a patient must be about 18 to start accumulating tattoos. Stephen A. Hoption Cann, PhD As tattoos grow in popularity, patients increasingly seek advice from general practitioners and dermatologists about potential health risks. While adverse effects such as infections and allergic reactions are well-documented, the longer-term health implications of tattoos, particularly cancer risks, have only recently begun to receive more attention. Although this commentary centers on Canada, its implications extend globally. Let's explore the key concerns tattoos present in terms of cancer risks and how clinicians should approach them. A patient may wonder whether injecting all manner of inks into the dermal layers of their skin poses any long-term risks. One might assume, wrongly, that since tattoos have been around for a very long time that cancer risks would have been exhaustively investigated. While there have been many case reports noting the occurrence of various types of cancerous lesions within tattoos, they do not tell us whether this association is causal or coincidental. Epidemiological studies exploring this question are few. On the surface, it seems like an easy question to explore: Just compare cancer risk in those with tattoos to those without. However, one must remember that there are hundreds of brands and thousands of colors of ink on the market — and individual tattoos often contain many colors. Then there is the question of tattoo size. Moreover, if people stopped at one tattoo, that would make it much easier for epidemiologists; however, individuals who were happy with their first tattoo may go on to get many more over subsequent years, adding complexity to the calculation of an individual's overall exposure risk. Then there are the many confounding factors such as smoking, alcohol, socioeconomic status, etc, which must be accounted for. Before we get into the epidemiological studies, we might want to know how tattoo inks are regulated. Health Canada has created a list of restricted or prohibited ingredients of tattoo inks. This list includes substances that are considered mutagenic, carcinogenic, toxic to reproduction, skin sensitizers, and irritants. The regulator also samples and tests tattoo inks to check for microbial contamination, heavy metals, and labeling accuracy. The European Union has taken a similar approach, but the FDA does not approve tattoo inks. Its regulation is mostly passive (eg, investigating safety concerns when adverse reactions are reported). So, what can be found in these tattoo inks? Nonorganic inks can contain a virtual smorgasbord of metals, including barium, cadmium, chromium, cobalt, iron, nickel, lead, titanium, and mercury, though the latter largely has been phased out due to toxicity concerns. Some nonorganic inks contain acrylics or synthetic pigments. All these substances aid in long-term color retention. In contrast, organic inks are often made from plant-based or carbon-based pigments but tend to fade faster as they lack the metallic or synthetic stabilizers found in nonorganic inks. While the FDA requires accurate labeling of these products, a recent US study found that 83% of tattoo inks tested (45 of 54) had major label discrepancies — not that clients getting a tattoo would even read the label. Many of the metals used are known carcinogens (eg, cadmium, chromium, lead, mercury, and nickel) or possible carcinogens (eg, cobalt and titanium), depending on the chemical species. Additionally, some of the pigments used, such as azo dyes, can decompose into carcinogenic aromatic amines. Other harmful substances in inks include polycyclic aromatic hydrocarbons, which have been proven to be carcinogenic to animals and humans. What about cancer risks? Most studies to date have examined lymphomas, as it has been demonstrated in animal and human studies that most of the pigment from tattoos will be transported to regional lymph nodes. In this mostly final resting place, it could cause chronic inflammation and carcinogenic processes over time. A couple of case-control studies have found a significant increase in lymphoma risk in tattooed subjects relative to comparison groups (see Table). A well-designed twin study noted a higher risk, particularly for large tattoos (ie, bigger than the palm of the hand, which may not seem so large today). While another study from Sweden noted an elevated risk for lymphoma and lymphoma subtypes, no finding was significant. In contrast, a Canadian study found no trend for non-Hodgkin lymphoma, although tattoos were uncommon (around 5%) in the population studied. Several studies have examined risks for various types of skin cancer. A study on cosmetic tattoos showed a nonsignificant elevated risk for basal cell carcinoma. Clemmensen et al, who conducted a case-control and a cohort study, showed significantly elevated risk for skin cancer associated with large tattoos in the former study and elevated risks for skin cancer and basal cell carcinoma in the latter study. In contrast, a recent study by Liljedahl et al found no evidence of risk for cutaneous squamous cell carcinoma. Aside from lymphomas, a few other hematologic cancers have been studied, but nothing significant has been found. Table: Research into tattoos and cancer risk. Download Table as PDF Ultimately, many uncertainties about cancer risks remain, and thus it is not surprising that some larger cohort studies have been established to answer these questions. A couple of examples include Tattoo inK, a cohort study of about 18,000 tattooed individuals and 160,000 untattooed controls within the German National Cohort, and Cancer Risk Attributable to the Body Art of Tattooing, a cohort study of about 13,000 tattooed individuals and 100,000 untattooed controls, which is integrated into the French Consultants des Centres d'Examens de Santé (Constances) cohort. While these are ample cohorts, one may have to wait one or more decades for findings to accrue. A patient who smokes or drinks can quit to reduce his or her cancer risk. But what about a patient with a tattoo? The most common removal technique is laser therapy, which uses high-intensity light pulses to break down tattoo ink particles. Can this process remove the potentially hazardous particles? Well, not exactly, as these fragments end up being funneled into the draining lymph nodes. Sending more pigment into this region could increase risk, but we don't know for sure. Dermabrasion, chemical peels, or surgical removal can remove the ink but can also produce significantly more scarring and thus are usually reserved for smaller tattoos. So, you have a patient with a new tattoo who is eager to hit the beach to show it off. What do you tell them? First, they should be warned that sun exposure will accelerate fading. And those degraded pigments don't just disappear, they release potentially harmful substances into the body. There is also a possible increased risk for skin cancer, so they're better off displaying their tattoos indoors or using sun-protective clothing or sunscreen. Beyond skin issues, tattoos may also increase the risk of lymphomas, but we do not know this for sure. Nor do we know much about risks for other types of cancer. Finally, tattoo removal is not the quick fix that works for other risky habits. Thus, for the patient considering their first tattoo, or more tattoos, one might say that if they can hold off for just another 10 to 20 years, we should be able to give a more definitive answer. Alternatively, given the current evidence, it would be premature to assure patients that tattoos are entirely risk-free.
